BeyondSpring Announces Phase 3 Study 105 of its Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Meets Primary Endpoint at Interim Analysis

World News: . []

NEW YORK Dec 06 2018 GLOBE NEWSWIRE -- NASDAQ BYSI a global biopharmaceutical company focused on the development of innovative cancer therapies today announced that the Phase 3 portion of its pivotal Study 105 evaluating its lead asset , Plina...

More news and information about BeyondSpring, Inc.

Published By:

Globe Newswire: 12:30 GMT Thursday 6th December 2018

Published: .

Search for other references to "beyondspring" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us